Probing the world of cytochrone P450 enzymes

被引:51
作者
Frye, RE [1 ]
机构
[1] Univ Florida, Coll Pharm, Dept Pharm Practice, Gainesville, FL 32610 USA
[2] Univ Florida, Coll Pharm, Ctr Pharmacogenom, Gainesville, FL 32610 USA
关键词
D O I
10.1124/mi.4.3.5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Variability in drug response can be attributed in part to variability in the activity of drug-metabolizing enzymes. One of the most important drug-metabolizing enzyme systems in humans is the cytochrome P450 (CYP) enzyme family, which is responsible for the oxidative metabolism of numerous endogenous compounds and xenobiotics. The clinical relevance of factors that influence CYP-mediated metabolism can be appreciated by estimating in vivo enzyme activity (Le., the phenotype) through the use of "probe drugs," which are drugs predominately or exclusively metabolized by an individual CYP enzyme. Thus, the use of probe drugs alone or in combination (Le., the cocktail approach) can provide an invaluable tool to explore the clinical relevance of genetic and nongenetic factors that affect CYP (Enzyme activity and thereby contribute substantially to variability in response to therapeutic drugs.
引用
收藏
页码:157 / 162
页数:6
相关论文
共 33 条
[1]   Molecular genetics of CYP2D6:: Clinical relevance with focus on psychotropic drugs [J].
Bertilsson, L ;
Dahl, ML ;
Dalén, P ;
Al-Shurbaji, A .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (02) :111-122
[2]   Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions [J].
Bertz, RJ ;
Granneman, GR .
CLINICAL PHARMACOKINETICS, 1997, 32 (03) :210-258
[3]   The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective [J].
Bjornsson, TD ;
Callaghan, JT ;
Einolf, HJ ;
Fischer, V ;
Gan, L ;
Grimm, S ;
Kao, J ;
King, SP ;
Miwa, G ;
Ni, L ;
Kumar, G ;
McLeod, J ;
Obach, RS ;
Roberts, S ;
Roe, A ;
Shah, A ;
Snikeris, F ;
Sullivan, JT ;
Tweedie, D ;
Vega, JM ;
Walsh, J ;
Wrighton, SA .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (07) :815-832
[4]   A COCKTAIL STRATEGY TO ASSESS INVIVO OXIDATIVE DRUG-METABOLISM IN HUMANS [J].
BREIMER, DD ;
SCHELLENS, JHM .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1990, 11 (06) :223-225
[5]   The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes [J].
Christensen, M ;
Andersson, K ;
Dalén, P ;
Mirghani, RA ;
Muirhead, GJ ;
Nordmark, A ;
Tybring, G ;
Wahlberg, A ;
Yasar, Ü ;
Bertilsson, L .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (06) :517-528
[6]   Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians [J].
Dalén, P ;
Dahl, ML ;
Roh, HK ;
Tybring, G ;
Eichelbaum, M ;
Wilkinson, GR ;
Bertilsson, L .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 55 (06) :630-634
[7]   Pharmacogenetics of the major polymorphic metabolizing enzymes [J].
Daly, AK .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2003, 17 (01) :27-41
[8]   Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans [J].
Dickmann, LJ ;
Rettie, AE ;
Kneller, MB ;
Kim, RB ;
Wood, AJJ ;
Stein, CM ;
Wilkinson, GR ;
Schwarz, UI .
MOLECULAR PHARMACOLOGY, 2001, 60 (02) :382-387
[9]   A FAMILY AND POPULATION STUDY OF THE GENETIC-POLYMORPHISM OF DEBRISOQUINE OXIDATION IN A WHITE BRITISH-POPULATION [J].
EVANS, DAP ;
MAHGOUB, A ;
SLOAN, TP ;
IDLE, JR ;
SMITH, RL .
JOURNAL OF MEDICAL GENETICS, 1980, 17 (02) :102-105
[10]   Drug therapy - Pharmacogenomics - Drug disposition, drug targets, and side effects [J].
Evans, WE ;
McLeod, HL .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (06) :538-549